当前位置: X-MOL 学术Clin. Exp. Ophthalmol. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Intravitreous treatment of severe ocular von Hippel–Lindau disease using a combination of the VEGF inhibitor, ranibizumab and PDGF inhibitor, E10030: Results from a phase 1/2 clinical trial
Clinical & Experimental Ophthalmology ( IF 4 ) Pub Date : 2021-09-21 , DOI: 10.1111/ceo.14001
Christopher K Hwang 1 , Emily Y Chew 1 , Catherine A Cukras 1 , Tiarnan D L Keenan 1 , Wai T Wong 2 , W Marston Linehan 3 , Prashant Chittiboina 4 , Karel Pacak 5 , Henry E Wiley 1
Affiliation  

Treatment options for severe ocular von Hippel–Lindau (VHL) disease are limited. This trial evaluated preliminary safety and potential efficacy of combination intravitreous injection with ranibizumab, a vascular endothelial growth factor (VEGF) inhibitor, and E10030, a PDGF inhibitor, for eyes with VHL disease-associated retinal hemangioblastoma (RH) not amenable or responsive to thermal laser photocoagulation.

中文翻译:

使用 VEGF 抑制剂、雷珠单抗和 PDGF 抑制剂 E10030 的组合对严重的眼部 von Hippel-Lindau 病进行玻璃体内治疗:1/2 期临床试验的结果

严重眼部 von Hippel-Lindau (VHL) 病的治疗选择有限。该试验评估了玻璃体内注射血管内皮生长因子 (VEGF) 抑制剂雷珠单抗和 PDGF 抑制剂 E10030 的初步安全性和潜在疗效,用于患有 VHL 疾病相关性视网膜血管母细胞瘤 (RH) 的眼睛不适合或对热反应不敏感激光光凝术。
更新日期:2021-09-21
down
wechat
bug